| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-063 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、关于非独立董事辞职的情况 广西柳药集团股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 28 日收到公司非独立董事、副总裁唐春雪女士提交的书面辞职报告。唐春雪女士因 公司内部工作调整原因，申请辞去公司第五届董事会非独立董事职务，辞职后仍 在公司担任副总裁。具体情况如下： （二）离任对公司影响 根据《公司法》《公司章程》等有关规定，唐春雪女士的辞职报告自送达公 司董事会之日起生效。唐春雪女士的辞职不会导致公司董事会成员人数低于法定 人数，不会影响公司董事会的正常运行，亦不会对公司的规范运作和日常生产经 营产生不利影响。 二、关于职工代表董事选举的情况 为进一步完善公司治理结构，根据《公司法》《上市公司章程指引》等法律、 法规及规范性文件和《公司章程》的相关规定，公司董事会中 ...

广西柳药集团股份有限公司 2025 年员工持股计划（草案）的 关于 深圳市福田区深南大道 4011 号香港中旅大厦 21-26 层 邮政编码（Postcode）：518048 21-26/F, HKCTS Tower, 4011 Shennan Road, Futian District, Shenzhen, P. R. China 电话（Tel.）：0086-755-83025555 传真（Fax.）：0086-755-83025068 网址（Website）：www.huashanglawyer.com | | | 法律意见书 广东华商律师事务所 法律意见书 在《广东华商律师事务所关于广西柳药集团股份有限公司 2025 年员工持股 计划（草案）的法律意见书》中，除上下文另有解释或说明外，下列使用的简称 分别代表如下全称或含义： 关于广西柳药集团股份有限公司 2025 年员工持股计划（草案）的 法律意见书 致：广西柳药集团股份有限公司 广东华商律师事务所（以下简称"本所"）接受贵公司的委托，担任贵公司 实施 2025 年员工持股计划的专项法律顾问。根据《中华人民共和国公司法》《中 华人民共和国证券法》《关于 ...

Core Viewpoint - Liuyao Group's stock has experienced fluctuations, with a recent decline of 2.03% and a total market capitalization of 7.109 billion yuan, indicating potential investor concerns and market volatility [1]. Financial Performance - For the period from January to March 2025, Liuyao Group reported a revenue of 5.317 billion yuan, representing a year-on-year decrease of 7.93%. The net profit attributable to shareholders was 277 million yuan, down 7.66% compared to the previous year [2]. - Cumulatively, Liuyao Group has distributed a total of 1.789 billion yuan in dividends since its A-share listing, with 720 million yuan distributed over the last three years [3]. Shareholder and Market Activity - As of March 31, 2025, the number of Liuyao Group's shareholders increased by 6.08% to 33,200, while the average number of circulating shares per person decreased by 5.73% to 11,948 shares [2]. - The stock's trading activity showed a net outflow of 23.3167 million yuan from major funds, with significant selling pressure observed [1].

证券日报网讯8月22日晚间，柳药集团（603368）发布公告称，截至2025年8月22日，公司通过集中竞价 交易方式回购股份数量为437.38万股，已回购股份占公司目前总股本的比例为1.10%。 ...

格隆汇8月22日丨柳药集团(603368.SH)公布，截至2025年8月22日，公司通过集中竞价交易方式回购股 份数量为437.38万股，已回购股份占公司目前总股本的比例为1.10%，回购成交的最高价为18.60元/股、 最低价为18.22元/股，已支付的总金额为8,073.03万元（不含交易费用）。 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式回购股份比例达到 1%暨 回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 7 7 | 25 | 日~2026 | 年 | 月 | 24 | 日 | | 预计回购金额 | 10,000万元~20,000万元 □减少注册资本 | | | | | | | | 回购用途 | √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累 ...

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

跟踪1000价值稳健的公募基金包括：华夏中证智选1000价值稳健策略联接A、华夏中证智选1000价值稳 健策略联接C、华夏中证智选1000价值稳健策略ETF。 从指数持仓来看，中证智选1000价值稳健策略指数十大权重分别为：方大特钢（1.22%）、金田股份 （1.16%）、奥士康（1.08%）、申通快递（1.08%）、吉比特（1.03%）、康缘药业（1.01%）、骆驼股 份（0.99%）、宁波华翔（0.98%）、柳药集团（0.98%）、塔牌集团（0.97%）。 从中证智选1000价值稳健策略指数持仓的市场板块来看，深圳证券交易所占比51.69%、上海证券交易 所占比48.31%。 从中证智选1000价值稳健策略指数持仓样本的行业来看，工业占比26.06%、原材料占比17.88%、医药 卫生占比14.26%、可选消费占比12.33%、信息技术占比8.56%、公用事业占比5.08%、通信服务占比 4.50%、主要消费占比4.42%、金融占比3.78%、能源占比1.61%、房地产占比1.54%。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Market Overview - The Shanghai Composite Index increased by 2.11% to close at 3635.13 points, with a weekly high of 3645.37 points [1] - The Shenzhen Component Index rose by 1.25% to 11128.67 points, reaching a peak of 11229.59 points [1] - The ChiNext Index saw a 0.49% increase, closing at 2333.96 points, with a maximum of 2372.68 points [1] - Global markets also experienced gains, with the Nasdaq Composite up by 3.87%, the Dow Jones Industrial Average rising by 1.35%, and the S&P 500 increasing by 2.43% [1] - In the Asia-Pacific region, the Hang Seng Index rose by 1.43% and the Nikkei 225 increased by 2.5% [1] New Stock Issuance - One new stock was issued last week: Zhigao Machinery (920101.BJ) on August 5, 2025 [2] Margin Trading - The total margin trading balance in the Shanghai and Shenzhen markets reached 20031.09 billion yuan, with a financing balance of 19889.53 billion yuan and a securities lending balance of 141.56 billion yuan [3] - The margin trading balance increased by 294.86 billion yuan compared to the previous week [3] - The top three stocks by financing purchase amount were Northern Rare Earth (58.53 billion yuan), Zhongji Xuchuang (49.9 billion yuan), and Dongfang Fortune (48.27 billion yuan) [3][4] Fund Issuance - A total of 21 new funds were issued last week, including various index funds and mixed funds [5] - Notable funds include Ping An Ru Yi Short-term Bond Fund and Penghua CSI Bank Index Fund [5][6] Company Buybacks - There were 23 buyback announcements last week, with the highest amounts executed by Junxin Environmental Protection (50.99 million yuan), Mianbao (12.13 million yuan), and Runze Technology (10.47 million yuan) [7] - The sectors with the highest buyback amounts were Environmental Protection, Pharmaceutical Biology, and Electronics [7][8]